Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysis

Koji Sasaki, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi, Koichi Takahashi, Marina Konopleva, Gautam Borthakur, Guillermo Garcia-Manero, William Wierda, Naval Daver, Preetesh Jain, Toshihisa Satta, Sherry Pierce, May Beth Rios, Jorge E. Cortes

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Fingerprint

Dive into the research topics of 'Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysis'. Together they form a unique fingerprint.